On November 18, 2019 AgilVax Inc., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics, reported that preclinical data describing M5, the Company’s monoclonal antibody targeting xCT, will be presented by Dr. Salameh at the American Association for Cancer Research (AACR) (Free AACR Whitepaper)’s Tumor Immunology and Immunotherapy Conference being held at the Boston Marriott Copley Place in Boston, MA (Press release, Agilvax, NOV 18, 2019, View Source [SID1234551435]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title:

Development of a monoclonal antibody targeting xCT/SLC7A11 expressed in metastatic cancer cells

Poster Session:

Poster Session B

Session Date:

Tuesday, November 19

Board Number (poster number):

B37

Time:

4:30 p.m. to 7:00 p.m.

Session Location:

Back Bay

"We are pleased with our continued progress on developing multiple solutions to target cancer cells overexpressing xCT and thrilled to have the opportunity to showcase our advancements in a poster presentation at such a prestigious meeting," said Dr. Joseph Patti, President and CEO of AgilVax. Dr. Patti further stated, "xCT overexpression occurs in several cancers leading to metabolic changes that reprograms cells for growth and progression. AgilVax’s antibody-based therapeutics have shown reduction of primary tumor formation and lung metastases illustrating the potential to create durable responses in patients suffering from colorectal and other metastatic cancers.